| Item Type | Name |
|
Concept
|
Aged
|
|
Concept
|
Aged, 80 and over
|
|
Concept
|
Androgens
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Bayes Theorem
|
|
Concept
|
Benzamides
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Bridged-Ring Compounds
|
|
Concept
|
Humans
|
|
Concept
|
Indazoles
|
|
Concept
|
Insurance Carriers
|
|
Concept
|
Health Knowledge, Attitudes, Practice
|
|
Concept
|
Longitudinal Studies
|
|
Concept
|
Middle Aged
|
|
Concept
|
Multiple Sclerosis
|
|
Concept
|
Patient Acceptance of Health Care
|
|
Concept
|
Phenylthiohydantoin
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
United States
|
|
Concept
|
Health Care Costs
|
|
Concept
|
Patient Satisfaction
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Receptor, ErbB-2
|
|
Concept
|
Cyclin-Dependent Kinases
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
BRCA1 Protein
|
|
Concept
|
Neoadjuvant Therapy
|
|
Concept
|
BRCA2 Protein
|
|
Concept
|
Recombinational DNA Repair
|
|
Concept
|
Triple Negative Breast Neoplasms
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Ataxia Telangiectasia Mutated Proteins
|
|
Academic Article
|
Payer perceptions of the use of real-world evidence in oncology-based decision making.
|
|
Academic Article
|
RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain.
|
|
Academic Article
|
Payer perceptions on the use of patient-reported outcomes in oncology decision making.
|
|
Academic Article
|
Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.
|
|
Academic Article
|
Payer perceptions on the use of economic models in oncology decision making.
|
|
Academic Article
|
Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.
|
|
Academic Article
|
BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel.
|
|
Academic Article
|
Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries.
|
|
Academic Article
|
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
|
|
Academic Article
|
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
|
|
Academic Article
|
Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States.
|
|
Academic Article
|
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.
|
|
Academic Article
|
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
|
|
Academic Article
|
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.
|
|
Academic Article
|
Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults With Metastatic Prostate Cancer.
|